Eugene Gerner of the Arizona Cancer Center named a Leading Edge Researcher at The University of Arizona

Eugene W. Gerner, PhD
Eugene W. Gerner, PhD

FOR IMMEDIATE RELEASE
March 25, 2009
Contact: Marisa Allen (520) 626-5752

TUCSON, Ariz. – Eugene W. Gerner, PhD, director of the Arizona Cancer Center’s Gastronitestinal (GI) Cancer Program and the National Cancer Institute-funded Specialized Program of Research Excellence (SPORE) in GI Cancers, has been named a Leading Edge Researcher at the University of Arizona.

Gerner was honored at the UA’s sixth annual Innovation Day celebration March 24. He was cited for his development of a two-drug combination shown to reduce the risk of recurrent colorectal polyps, a precursor to colon cancer, by up to 95 percent with minimal toxicity.

Gerner, a professor of cell biology and anatomy and a member of BIO 5 Institute at the UA, is a co-founder of Cancer Prevention Pharmaceuticals LLC, established to develop therapies to prevent cancer in people with elevated risks for the diseases.

“This award could not have been given to a more brilliant or deserving scientist,” said Arizona Cancer Center Director David S. Alberts, MD. “Dr. Gerner has been in the Arizona Cancer Center for 35 years and has continued to make seminal scientific accomplishments in the areas of prevention, early detection and treatment of gastrointestinal GI precancerous lesions and invasive GI cancers. His work is internationally recognized as the best in polyamine function and action.”